skip to Main Content

Sequencing Strategies May Shift With Emerging Options in GI Malignancies

Newsfeed image, light gray text on dark gray background
With the rapid uptake of novel therapies, including immunotherapy and targeted therapy, shifts in treatment strategies are anticipated in hepatobiliary cancers, locally advanced and advanced pancreatic cancer, gastric/gastroesophageal junction cancers, and metastatic colorectal cancer (mCRC), according to a panel of experts from the University of Southern California (USC) Norris Comprehensive Cancer Center that presented during an OncLive® Institutional Perspectives in Cancer webinar on gastrointestinal malignancies.


Notably, Anthony El-Khoueiry, MD, co-chair of the event, associate professor of clinical medicine in the Division of Medical Oncology, member of the Gastrointestinal Cancers Program, director of the Phase I Drug Development Clinical Program, and medical director of the Clinical Investigations Support Office at the University of Southern California (USC) Norris Comprehensive Cancer Center, shed light on the evolving frontline paradigms in hepatobiliary cancers that could challenge current standards of care. Read more. . .

Back To Top